Biotechnology - RNA Therapeutics / Genetic Medicine
Strategic Profile
Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. The company has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.
Cyborg Score Rationale
Silence is a clinical-stage biotech with differentiated siRNA technology and high-value pharma partnerships, but carries typical biotech execution and capital requirements risks. Recent Phase II data for lead cardiovascular program provides validation, but multiple programs remain early stage with regulatory and clinical uncertainties ahead.
Top Insights
Lead program Zerlasiran (SLN360) in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a)
Strategic partnership with AstraZeneca for siRNA therapeutics across cardiovascular, renal, metabolic, and respiratory disease areas
Divesiran (SLN124) in Phase I clinical trial for genetic hematological conditions including polycythemia vera
Clinical-stage biotech dependent on successful trial outcomes and regulatory approvals for pipeline programs
Named Competitors
Antisense/siRNA therapeutics — Leading antisense and siRNA therapeutic developer
siRNA therapeutic platform — RNA therapeutics and delivery platform developer
Cardiovascular therapeutics — Pharma partner on Silence's cardiovascular program expansion
Recent Developments
(February 2025) Q4 2024 earnings call conducted with recent Phase 2 ALPACAR-360 study data for zerlasiran in ASCVD patients
(September 2025) Presentation at Morgan Stanley 23rd Annual Global Healthcare Conference
(2024) Continued advancement of Divesiran and SLN548 programs in development
Open the full interactive Silence Therapeutics plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.